Novel Anti-MARCKS Platform
We Bring Expertise in Research and New Drug Development
Biomarck has assembled a management team, Board of Directors and Scientific Advisory Board with extensive experience in new drug development, clinical practice, and clinical research, to rapidly advance a pipeline of MARKS protein inhibitors for multiple indications.
Board of Directors
Scientific Advisory Board
Our Partners Lead the Way in Bringing Therapies to Patients in Need
North Carolina State University
Biomarck has a long and rewarding history of collaboration with the laboratory of Kenneth Adler, Ph.D., a Professor of Molecular Biomedical Sciences at North Carolina State University. When Dr. Adler began studying MARCKS in the late 1990’s, there were no known ways to inhibit the biological function of MARCKS protein and its role in several biological processes was merely correlative. Dr. Adler’s laboratory developed the MANS peptide, which was shown to block MARCKS function in a variety of cell types, including airway epithelial cells and inflammatory cells. The MANS peptide is the basis for the development of BIO-11006. Dr. Adler has been the recipient of continuous long-term research funding from the National Institute of Health (NIH), and in 2004 received a MERIT award from NHLBI. He has served as Chair of the NIH Lung Biology and Pathology and Lung Cellular and Molecular Immunology study sections.
National Institutes of Health (NIH)
Biomarck has been awarded a succession of grants from the NIH and related entities, including a Phase I SBIR Grant for $100,000 in 2003, a Phase II SBIR Grant for $1,228,000 in 2004, a Phase III SBIR Grant for $2,990,000 in 2006, a SBIR Grant for $3,000,000 in 2014, and a STTR Grant for $201,503 in 2014.
Live Like Bella Foundation
Biomarck has a limited compassionate use program in place that has supported children with difficult to treat cancers, such as rhabdomyosarcoma and neuroblastoma, as part of a collaboration with the Live Like Bella Foundation. To learn more, visit our page on Expanded Access.